Increasing the use of long-acting medications for opioid addiction treatment.
Adoption and scale-up of long-acting medications for opioid use disorder by U.S. clinicians.
This study is looking at how doctors in the U.S. start using long-lasting medications to help people with opioid addiction, and it aims to find out what makes it easier or harder for them to prescribe these treatments, so that more patients can get the help they need.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11089592 on NIH RePORTER |
What this research studies
This research focuses on understanding how U.S. clinicians adopt long-acting medications for treating opioid use disorder (OUD). It aims to identify the barriers and facilitators that affect the prescribing of these medications, which include monthly injectable naltrexone and implantable buprenorphine. By analyzing insurance claims data and clinician behaviors, the research seeks to improve the delivery of effective treatments for OUD in both primary care and specialty settings. The findings could help enhance the availability and use of these medications for patients struggling with opioid addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who may benefit from long-acting medication treatments.
Not a fit: Patients who are not diagnosed with opioid use disorder or those who do not require medication-assisted treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to increased access to effective long-acting treatments for patients with opioid use disorder.
How similar studies have performed: Previous research has shown that increasing access to long-acting medications can improve treatment outcomes for opioid use disorder, suggesting that this approach has potential for success.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Shover, Chelsea Leigh — University of California Los Angeles
- Study coordinator: Shover, Chelsea Leigh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.